Analyzing Mineralys Therapeutics (NASDAQ:MLYS) and Tenaya Therapeutics (NASDAQ:TNYA)

Tenaya Therapeutics (NASDAQ:TNYA) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Earnings & Valuation

This table compares Tenaya Therapeutics and Mineralys Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60 million	($0.47)	-1.68
Mineralys Therapeutics	N/A	N/A	-$154.65 million	($2.05)	-13.18

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Tenaya Therapeutics has a beta of 2.83, indicating that its share price is 183% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

Profitability

This table compares Tenaya Therapeutics and Mineralys Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Analyst Recommendations

This is a summary of current ratings and price targets for Tenaya Therapeutics and Mineralys Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1	0	5	1	2.86
Mineralys Therapeutics	1	1	6	0	2.62

Tenaya Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 406.97%. Mineralys Therapeutics has a consensus target price of $49.33, indicating a potential upside of 82.65%. Given Tenaya Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Tenaya Therapeutics is more favorable than Mineralys Therapeutics.

Insider and Institutional Ownership

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Tenaya Therapeutics beats Mineralys Therapeutics on 8 of the 12 factors compared between the two stocks.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.